We leverage public and private partnerships to catalyze change in the lives of those affected by rare autoimmune optic nerve diseases. These diseases include NMOSD, MOGAD, Inflammatory Optic Neuropathy, Antibody-Mediated Optic Neuritis, Idiopathic Optic Neuritis, and Seronegative Optic Neuritis.